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Abstract
Spinal cord injury (SCI) is a phenomenon characterized by damage to the spinal cord
and nerve roots, resulting in loss of physiological activity below the lesion. Injury to the
spinal cord activates a cascade of cellular and molecular reactions in which the immune
system plays an essential role, as there is an uncontrolled immune response that endows
further damage to neural tissue. However, the activity of immune system at the site of
injury can be modified in order to obtain a neuroprotective environment and promote
SCI recovery. This strategy has been designed under the light of the innovative concept
“protective autoimmunity” (PA) and can be stimulated with the use of altered peptide
ligands  (APL).  Adequate  immunomodulation with  APL can be  obtained with  the
peptide A91, which is a safe synthetic peptide derived from the myelin basic protein
(MBP) that has proven to be effective in preclinical research. Immunization with A91 is
carried out with the objective of preventing further damage and promoting neuropro‐
tection.  This peptide has direct  influence over SCI secondary mechanisms such as
inflammation,  lipid  peroxidation,  and  apoptosis.  Preclinical  results  suggest  that
immunization with A91 could be an effective treatment in the clinical field, providing
a better quality of life to SCI patients.
Keywords: spinal cord injury, protective autoimmunity, A91, altered peptide ligand,
immunization
1. Introduction
Spinal cord injury (SCI) is perhaps one of the most devastating conditions as it results in a
disruption of motor, sensory, and autonomic functions, leading to permanent neurological
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disability. According to the National Spinal Cord Injury Statistical Center (NSCISC), in 2014
over 276,000 people were suffering from SCI [1]. The incidence ranges over 12,500 new cases
each year, with a prevalence of approximately 40 cases per million in the United States [2].
Epidemiological studies indicate that SCI has a higher incidence among male population, and
people between 30 and 50 years old [3, 3]. Clinically, the most disabling outcomes of traumat‐
ic SCI are motor deficit and sensory loss. Nonetheless, due to autonomic dysfunction and
depending on the level and severity of injury, SCI may also alter normal homeostasis and the
respiratory,  reproductive,  urinary,  and  gastrointestinal  systems  [4–6].  Besides  surgical
intervention, the standard of care for SCI in several countries focuses on preventing shock and
further damage with the use of methylprednisolone (MP), a synthetic glucocorticoid with anti‐
inflammatory properties. The National Acute Spinal Cord Injury Study (NASCIS) trials suggest
that high‐dose MP is effective for the management of acute SCI [5, 8]. However, further studies
about NASCIS results indicate that the clinical benefits of the use of MP as a treatment for SCI
are questionable [6, 10]. Acute MP therapy reduces cellular damage and secondary injury
mechanisms but leads to risks of high‐dose steroids [7]. For this reason, MP administration after
SCI is still a controversial treatment, and it continues to be debated [8].
Another molecule that has been widely studied for the clinical treatment of SCI is Ganglioside,
which is highly expressed in the cell membranes of the central nervous system (CNS). The
synthetic form of this glycosphingolipid—monosialotetrahexosylganglioside (GM1)—was
known for having anti‐apoptotic, anti‐excitotoxic, and neuroprotective properties [9, 14].
Therefore, several clinical trials were designed in order to test this drug on SCI [10]. In the most
recent study, patients received NASCIS II doses of MP, and different doses of GM1 after the
effect of MP was over. Although, GM1 treated patients presented a significant recovery, the
beneficial effects related to the drug were inconsistent between different types of injuries and
were lost during chronic SCI stages [11, 17]. These results suggest that GM1 has a limited effect
and to the date, it is not an approved treatment for SCI [12].
Undoubtedly, the lack of an available treatment for SCI in the clinical field highlights the need
to design new and safe therapies for injured patients. Nowadays, research is focused on
targeting secondary SCI mechanisms with the objective of minimizing further damage,
promoting regeneration and thus, improving functional recovery [13, 19]. One of the most
important secondary injury mechanisms is the post‐traumatic inflammatory response, which
is roughly characterized by the presence of injury‐dependent pro‐inflammatory cytokines and
infiltration of peripheral immune cells to the damaged area [14–22]. It was previously thought
that the presence of this uncontrolled immune response in the CNS was harmful and patho‐
logical. However, other findings state a controversial theory: immune cells could play an
essential role in neuroprotection and regeneration of the spinal cord after injury [15]. A better
understanding of how inflammation mediates secondary injury suggests that suppressing all
immune responses with the use of glucocorticoids is no longer a rational treatment approach.
This information has led scientists to further investigate the beneficial effects of the immune
system in several neurological conditions, including SCI [16]. Focusing on the beneficial
mechanisms of the immune system after trauma has opened the doors for the design of a new
therapeutic strategy. Nevertheless, some questions should first be answered. For instance, how
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can the immune system be modulated to attain a protective microenvironment? What are the
immune‐related elements capable of providing the required immune‐modulation? And how
are they able to provide recovery after SCI?
2. Spinal cord injury pathophysiology
Damage to the spinal cord (SC) causes anatomical and functional deficits to the CNS, that result
in the appearance of several long‐term medical comorbidities. SCI is characterized by two
different pathophysiological phases: primary and secondary injury [17]. Initial trauma to the
SC—known as primary injury—is caused by a compressive or contusive mechanism that
results in gross anatomical tissue disruption, and immediate hemostatic self‐defense events
that produce further damage to CNS structures. Direct impact to the SC leads to vascular
disturbances such as hemorrhage, ischemia, edema, and hypoperfusion, resulting in tissue
necrosis [18]. Hemorrhage and edema formation can raise the risk of developing increased
parenchymal pressure and produce more tissue damage [19]. Also, reactive gliosis, demyeli‐
nation, and axonal loss are often caused by immediate trauma and sustained compression to
neural tissue [20]. Depending upon primary injury characteristics, there could be greater tissue
damage and worse functional outcomes. Therefore, during this phase, treatment should focus
on hemorrhage control to avoid necrosis and early decompression to stabilize intrathecal
pressure.
As a consequence of primary injury, there is a cascade of biological reactions that occur minutes
after injury and last for several weeks known as secondary injury [21]. This phase is quite
complex, as it consists of the development of mechanisms like loss of ATP‐dependent cellular
functions, ion homeostasis imbalance, excitotoxicity, oxidative stress, lipid peroxidation,
inflammation, and apoptosis [22]. There are several secondary mechanisms that are strongly
related to the ischemic event observed in SCI. Ischemia produces a depletion of the intracellular
amount of ATP, leading to a reduction in the energy‐dependent cell function that preserve ion
homeostasis [23]. Therefore, the sodium‐potassium pump cannot execute its physiological
activity, resulting in an elevated potassium (K+) efflux, and a high influx of sodium (Na+),
calcium (Ca2+), and chloride (Cl-) into the cell. This homeostasis imbalance alters normal ion
concentrations within the intracellular and extracellular spaces, producing a sustained
membrane depolarization and a release of excitatory amino acid (EAA) neurotransmitters [24].
The pathological effect related to an increased concentration of EAA neurotransmitters, such
as glutamate and aspartate, is known as excitotoxicity. This secondary injury mechanism is
characterized by an overstimulation of the NMDA, kainate and AMPA glutamate receptors,
which causes massive intracellular Ca2+ concentrations, resulting in a pathological neuronal
excitation and cell death [25, 32]. Glial cells—especially oligodendrocytes—are very sensitive
to excitotoxic damage because of their high expression of ionotropic glutamate receptors [26].
That is why an excessive glutamate accumulation related to SCI can produce oligodendrocyte
death, and consequent white matter demyelination [27]. Also, because of glutamate excito‐
toxicity, there is an increased production of free radicals by reactive microglia, which contrib‐
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ute to lipid peroxidation (LP), and mitochondrial dysfunction [28, 36]. Therefore, this sustained
toxic microenvironment is postulated to be one of the most detrimental secondary injury
mechanisms related to SCI.
Oxidative stress accompanies secondary injury damage, and is mainly characterized by an
increased mitochondrial production of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) [29, 38]. The elevation in ROS and RNS concentration is closely related to the
aforementioned high Ca2+ influx to the cells, as it stimulates free radical production [30]. Free
radicals such as superoxide anion (O2-), nitric oxide (NO), and peroxynitrite (ONOO-) create a
toxic microenvironment by oxidizing nearby molecules producing neural energy failure,
blood‐brain barrier dysfunction, vascular reactivity, and potentiating inflammation [31, 41].
At high concentrations, these molecules can become cytotoxic and worsen secondary injury
mechanisms [32]. Oxidative stress also influences excitotoxicity by exacerbating Ca2+ deregu‐
lation and thus, glutamate concentrations. The pathological production of ROS that arises after
trauma causes oxidative damage, especially on lipids, originating LP. LP is characterized by
producing a disruption in the normal structure of the polyunsaturated fatty acids in the cell
membrane, such as arachidonic acid, and linoleic acid. In LP, the high concentration of free
radicals, results in functional compromise and cell death [33, 43]. Also, structural damage to
the cell membrane produces a reduction in the generation and transmission of the electrical
potentials leading to synapse dysfunction [34]. Altogether these mechanisms potentiate
apoptosis, which is a form of programmed cell death characterized by cell shrinkage, nuclear
pyknosis, and chromatin aggregation in a stressful environment [35]. This deleterious event,
(apoptosis) occurs after SCI by stimulation of the apoptosis‐inducing factor (AIF) to the
nucleus, or by direct mitochondrial disruption leading to a subsequent activation of caspase‐
3 signaling pathways [36, 47]. Evidence supports that secondary injury mechanisms contribute
to delayed tissue damage, exacerbating damage, and limiting recovery after traumatic SCI.
2.1. Pathophysiological involvement of the immune system
The immune system has a pivotal and somehow controversial role within the pathophysiology
of traumatic SCI. Immediately after trauma there is an activation of the inflammatory response
that consists in the proliferation of resident microglia and astrocytes, a high concentration of
pro‐inflammatory molecules, and infiltration of peripheral immune cells to the site of injury
(Figure 1). SCI induces the activation of a series of inflammatory stimuli leading to an increased
concentration of cytokines and inflammatory cells that will determine the extent of secondary
damage [37]. Evidence suggests that in the presence of an excitotoxic and inflammatory
microenvironment, microglial cells differentiate into a M1 pro‐inflammatory phenotype [38].
Under these conditions, activated microglia is capable of secreting interleukin 1β (IL‐1β), IL‐
6, tumor necrosis factor‐alpha (TNFα), and macrophage colony‐stimulating factor (MCSF)
which are pro‐inflammatory in nature [39].
A high free radical and cytotoxic substances secretion is more evident when there is microglial
activation starting at day one, and increasing at 7 days post‐injury [40]. That is why the immune
response is closely related to LP, as these cells are capable of boosting ROS and NO concen‐
trations, favoring oxidative stress, cell membrane dysfunction and thus, apoptosis [41, 50]. At
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the same time, TNFα stimulates astrocyte proliferation and growth, leading to the formation
of the glial scar within the chronic stages of SCI impeding axonal regeneration through the site
of injury [42, 53]. Glial cells act immediately after trauma; they secrete pro‐inflammatory
molecules and promote inflammation, favoring the appearance of secondary injury mecha‐
nisms. In spite of the above mentioned deleterious effects, microglial—especially when
differentiated into an M2 phenotype (IL‐10 and TGF‐beta)—and astrocyte activation could
produce a beneficial effect through a high production of growth factors like brain derived
neurotrophic factor (BDNF), and neurotrophin‐3 (NT‐3), essential for tissue repair [43]. Also,
these cells are capable of expressing glutamate transporters that help reducing harmful
Figure 1. Cellular immune response in SCI. A. M1 microglial differentiation, astrocyte activation, and IL‐1β, IL‐6, and
TNFα secretion. B. Increase in the concentration of ROS, NO, and RNS. C. Peripheral infiltration of neutrophils and
myeloperoxidase secretion. D. Macrophages arise from peripheral tissue and activate the adaptive immune response.
E. Infiltration of T‐lymphocytes to the site of injury and INFγ secretion. Abbreviations: IL, interleukin; RNS, reactive
nitrogen species; ROS, reactive oxygen species; NO, nitric oxide; TNFα, tumor necrosis factor‐alpha; INFγ, interferon‐
gamma; MYO, myeloperoxidase.
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concentrations, leading to a reduction in excitotoxicity [44]. Evidence suggests that even
though the immune system is considered to be completely pathological in nature, it can also
provide beneficial effects for SCI repair.
In normal conditions, inflammatory reaction leads the response to a pathological outcome,
promoting damage and spinal cord degeneration. The severity of SCI determines the intensity
of the inflammatory response and the glial reaction to SCI. Glial cells are well distributed
within the CNS, and have the ability to proliferate and migrate to the site of injury. In response
to injury there is a high glial secretion of cytokines and chemokines—such as IL‐1, IL‐6, and
TNFα—that allows migration of peripheral immune cells [45]. TNFα stimulates the expression
of adhesion molecules like endothelial intracellular adhesion molecule ‐1 (ICAM‐1) and
vascular cell adhesion molecule‐1 (VCAM‐1) altering the blood‐brain barrier permeability and
inducing a peripheral infiltration of immune cells to the CNS (Figure 1). Cell infiltration to the
CNS is considered the principal factor for tissue disruption and sustained neural damage. The
first peripheral cells to arrive at the site of injury are neutrophils [46]. These cells have the
ability to phagocyte and clear debris, but they also secrete ROS and RNS, as well as other
pathological proteolytic and oxidative enzymes like myeloperoxidase, producing greater
tissue damage [47, 58]. At the same time, macrophages arise from resident microglia or from
peripheral monocytes with the objective of removing cell debris and stimulating angiogenesis
[48]. These cells play an essential role in the immune response, as they help in the activation
and reclusion of the adaptive immune system cells. Microglia, astrocytes and dendritic cells
may act as antigen‐presenting cells (APC), leading to T lymphocyte activation, proliferation,
and infiltration to the site of injury [49]. Lymphocytes recognize the signal and proliferate
creating large numbers of clones, specific to the antigen being presented by the APC. At 3 days
post‐injury, there is an evident infiltration of T‐cells to the CNS, these cells determine the
intensity and continue on modulating the immune response to trauma [50]. In SCI, the presence
of T‐lymphocytes is considered detrimental as they secrete a Th1 cytokine profile including
interferon gamma (IFNγ) [51, 63]. IFNγ is a pro‐inflammatory cytokine capable of inducing
free radical production, increasing IL‐6, IL‐12, IL‐1β, and TNFα concentrations, and activating
apoptotic‐signaling pathways [52–65]. These events represent the immune activity within the
acute phases of SCI and if it is not well controlled it could turn into a chronic and degenerative
immune response.
When inflammation is modulated, i.e., we control the intensity of inflammatory response, the
type, the action, and the arrival of immune cells, we could expect a change in the final outcome.
With this regard, there is a strong evidence suggesting that lymphocytes could also have
favorable activity, as they are capable of synthesizing several growth factors, like BDNF, NT3,
and nerve growth factor (NGF) [53–68]. These molecules are known for being capable of
promoting a protective and regenerative environment for CNS disorders [54].
To the date, it is clear that the immune response appearing after SCI could be pathological if
it is not well controlled at the onset of SCI [55]. In a short period of time, this uncontrolled
response leads to the extensive recognition of CNS peptides, proteins, lipids, or nucleic acids
by the immune system [56]. This interaction between immune cells and CNS constituents—
like the MBP—promotes the activation of lymphocytes and thereby, the possible development
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of an autoimmune response [57, 72, 73]. As a result, higher levels of demyelination are noted,
leading to loss of sensitive and motor synapses. Also, several studies have identified that B
cells secrete self‐reactive antibodies and pro‐inflammatory cytokines, promoting autoimmune
activity [58, 75]. Therefore, the immune response elicited after SCI is considered to be one of
the most important secondary injury mechanisms, as it plays an essential role in stimulating
the appearance of a neurotoxic microenvironment after injury. However, further studies about
the immune system and its relationship with CNS damage suggest that it is not completely
pathological, as it has protective and regenerative properties [59–78].
3. Protective autoimmunity
The reactive immune response against self‐constituents appearing after injury has been widely
studied, as it can be an excellent target in the design of new therapies for SCI treatment. It was
previously thought that the presence of immune activity was detrimental and it had to be
suppressed [60–81]. However, more recent findings suggest that such response and the
infiltration of peripheral immune cells to the site of injury is a phenomenon destined to protect
and restore the CNS after trauma. The phenomenon capable of inducing this beneficial actions
has been termed protective autoimmunity (PA) and is a mechanism in which the adaptive
immune cells—especially lymphocytes that recognize self‐constituents and potentiate an
autoreactive response—help maintain tissue integrity in SCI. Researchers have demonstrated
that PA is genetically encoded, and it is a physiological phenomenon linked to the inflamma‐
tory activity in the CNS, capable of providing protection in several neurodegenerative
disorders [61, 83]. The immune system plays an essential role in tissue restoration, angiogen‐
esis, and is capable of increasing functional recovery in CNS trauma [62]. However, in normal
conditions the intense inflammatory response appearing after injury overshadows the
beneficial effects of PA. For that reason, it was thought that boosting PA after injury could
promote the beneficial instead of deleterious effects of the immune response to injury. In an
attempt to test this hypothesis, researchers performed a passive transfer of T‐cells specific to
MBP, and demonstrated that it reduced tissue damage and improved motor recovery in rats
with SCI [63, 86]. These studies suggested that the delayed adaptive immune response to injury
and the low concentration of autoreactive T‐cells are the reasons why PA is not evident, but a
higher and earlier presence of these cells could potentiate the beneficial effects of PA over SCI.
Shortly after researchers envisioned that active immunization could elicit a higher proliferation
and migration of autoreactive (antigen specific) T‐cells to the CNS increasing the action of PA.
Therefore, immunization with natural CNS components could help activate this response [64].
In line with this motion, several studies were performed indicating that, immunization with
MBP can modulate the immune response, potentiate PA, and provide neuroprotection to the
injured tissue [65, 88, 89]. In spite of the encouraging results, immune modulation with neural
constituents increases the risk of developing an autoimmune disease such as experimental
autoimmune encephalomyelitis (in rodents; EAE) or multiple sclerosis (in humans; MS) [66,
91]. For that reason, neural constituents were studied with the objective of creating a peptide
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capable of stimulating PA and reducing the risk of developing an autoimmune disease [67,
93]. These experiments led to the creation of altered peptide ligands (APL), which are synthetic
peptides with changes in specific amino acid residues, critical for T‐cell receptor (TCR) binding
[68]. In the normal immune response, the MBP has agonist properties as it interacts with the
TCR, leading to lymphocyte differentiation toward a Th1 phenotype [69, 96, 97]. With the
objective of altering TCR recognition, a specific amino acid substitution makes APL become
partial agonists or antagonists capable of deviating the immune response [70, 98]. That is why
APL are able to cause lymphocyte anergy or their differentiation to an anti‐inflammatory Th2
phenotype. This way, APL can alter the natural response of the immune system after SCI, by
being able to change the whole Th1 (pro‐inflammatory) cytokine profile toward a Th2 (anti‐
inflammatory) profile. Therefore, by altering the immune response, APL represent a good
therapeutic approach for the treatment of SCI and other neurodegenerative diseases [71, 99].
3.1. Modulation of protective autoimmunity with the use of altered peptide ligands
A safe and effective way of increasing PA is through immunization with APL [72]. This strategy
allows a change in the interaction with the TCR from an agonist to a partial agonist switching
the response toward a Th2 cytokine pattern [73]. To create APL, identification of the essential
residues of MBP for an acquired immune response to self‐determinants was investigated.
Evidence indicates that the amino acid sequence including the 87 to 99 residues is the most
encephalitogenic portion of the MBP and that it is essential for TCR recognition [74, 102]. This
amino acid sequence was fundamental for the creation of several APL and the evaluation of
their effect over the immune response [75]. Altering the amino acid sequence by substituting
each residue of the encephalitogenic region of the MBP with alanine, led to the discovery of
this group of APL [76, 104]. While trying to identify an ideal peptide to promote PA, several
APL derived from MBP encephalitogenic epitopes like G91, A96, or A97, along with A91 were
tested as therapeutic strategies for CNS trauma. These peptides were capable of controlling
the MBP peptide induced autoimmune reaction by altering the MBP specific T‐cell responses
[77]. Also, these APL demonstrated to be able of providing significant protection by reducing
neuronal loss [78]. More importantly, they were limited the extent of the immune secondary
injury mechanisms by inducing changes in the cytokine secretion profile of T‐cells and
enhanced the recovery of motor activity [79, 99, 103]. Studied APL showed different levels of
neuroprotection, however, the conclusion of these conducted studies was that the APL A91
provided the best therapeutic effects without the risk of an autoimmune response [80].
Evidence has demonstrated that lysine at the position 91 is an essential residue of the MBP
p87–99 for the development of a Th1 immune response. With this respect, it has been shown
that when the amino acid 91 (lysine) is replaced with glycine (G91), the peptide which is non‐
encephalitogenic, regulates the proliferative response and modifies the cytokine secretion
profile (toward a Th2 profile) of encephalitogenic MBP 87–99 reactive T‐cells [81, 99, 103, 104].
The substitution of lysine at the position 91 for the amino acid alanine led to the creation of
the APL: A91. This APL counteracts the production of pro‐inflammatory cytokines, generating
a microenvironment with anti‐inflammatory features [82, 103, 104]. A91 (amino acid sequence:
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VHFFANIVTPRTP) is a safe synthetic non‐encephalitogenic peptide, capable of inhibiting the
development of autoimmune disease while maintaining neuroprotection [83, 104]. This APL
(A91) has proven to be an effective TCR partial agonist capable of modulating the immune
response after CNS injury, and increasing the beneficial effects of PA. Immunization with
A91peptide down regulates Th1 activity and increases the levels of a Th2 cytokine pattern (IL‐
4 and IL‐10) creating an anti‐inflammatory microenvironment [84, 105, 106].
3.2. The altered peptide ligand A91 as a potential treatment for spinal cord injury
To increase neuroprotection, A91 was designed to boost PA and to act directly over secondary
mechanisms in SCI. Immunization with A91 has been tested as a subcutaneous injection, which
has resulted to be an effective and minimally invasive route of administration. The use of this
strategy in preclinical studies indicates that active immunization with A91 with a single dose
of 150–200 μg improves neurological recovery. It is important to note that in order to avoid
the risk of an autoimmune disease while maintaining neuroprotection, immunization with
myelin‐associated antigens should be fully controlled. A study evaluating the dose and
therapeutic window of A91 indicates that beneficial effect of this peptide lies between 10
minutes up to 72 hours after SCI [85]. Further studies also indicate that A91 could be considered
as a prophylactic therapeutic vaccine since its administration before SCI could provide high
levels of neuroprotection and motor recovery [86]. These results could be of relevant benefit
as an approach to provide with prophylactic measures to patients sustaining invasive spinal
surgery procedures.
On the other hand, with the objective of evaluating the effect of A91 immunization in the
presence of the gold standard treatment for SCI (MP) another study was carried out. The results
of this investigation indicated that when these two treatments were administered at the same
time, the beneficial properties of A91 were abolished [87]. However, the extensive therapeutic
time window of A91 enables immediate MP administration and immunization with A91 up
to 48 hours later [88, 109]. This approach has given the possibility of rescuing the beneficial
effects elicited by A91, as animals subjected to this combined strategy, present neuroprotection
and a higher motor recovery. These results also allow envisioning the possible clinical
application of this therapy with no risk of avoiding the therapeutic effects theoretically
provided by MP. In the search of increasing the neuroprotective effect of A91, double immu‐
nization has also been evaluated [89]. However, unexpectedly a higher concentration of this
peptide eliminates the beneficial aftermath of the therapy [90]. Studies in our laboratory have
also demonstrated that A91 can be applied at different SCI stages and still be effective. Our
investigation suggests that adequate immunization must be performed immediately after
injury or during the acute phase [91, 109]. Moreover, studies including vaccination of A91 in
chronic SCI are now being conducted, and results have demonstrated to be profitable (Un‐
published data).
APL were designed to specifically target the immune‐related secondary injury mechanisms in
order to attain neuroprotection, promote regeneration, and thus improving motor and sensory
recovery in SCI. In line with this, previous studies have shown that immunization with A91
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peptide produces an adequate T‐cell proliferation characterized by a Th2 phenotype, where
the production of IL‐4 and IL‐10 is increased [92, 110]. Additionally, A91 specific T‐cells are
capable of producing BDNF, which could be linked directly with the functional recovery
appearing after immunization [93]. This anti‐inflammatory and permissive microenvironment
controls the inflammatory response elicited by SCI, reducing some of the main harmful
phenomena developed by inflammation. For instance, it has been demonstrated that A91‐
immunization is capable of inhibiting LP, which is closely related to the action of immune
system and it is one of the most aggressive phenomena related to SCI [94]. LP is present
immediately after injury reaching its maximum peak at 4–5 h and has a second increase
between 24 hours and 5 days [95]. With this regard, a study conducted to evaluate the impact
of A91‐immunization on LP showed that A91 is able to reduce the concentration of ROS at the
site of injury having a strong impact over the second peak of this phenomenon [96]. A further
study indicated that A91‐immunization counteracts the production of nitric oxide (NO) and
down regulates the expression of the gene encoding for nitric oxide synthase (iNOS) [97]. These
are some of the beneficial mechanisms that explain, at least in part, the effect of this strategy
on LP.
Apoptotic cell death is another of the main destructive phenomena triggered after SCI. This
phenomenon is activated by inflammatory cytokines, free radicals, excitotoxic agents, and
increased levels of intracellular calcium [98]. After SCI, neurological recovery depends mainly
on the extent of neuronal loss and the functionality of the residual neural tissue. Numerous
studies have shown that many neurons die as a consequence of apoptosis. Therefore, regulat‐
ing apoptotic cell death might play an important role in the neurological recovery following
SCI [99, 116]. Recent investigations on the field found that immunizing with A91 decreases
caspase‐3 activity and TNFα concentrations, reducing the number of apoptotic cells, which is
directly correlated with functional improvement after injury [100].
Altogether, the aforementioned observations provide clear evidence on the mechanisms by
which A91‐immunization exerts its beneficial effects. Besides reducing secondary injury
mechanisms, A91 peptide has also proven to prevent tissue damage, as immunized animals
presented a higher number of myelinated axons and survival of rubrospinal neurons com‐
pared to controls [101, 109, 110]. These results were consistent throughout several SCI
preclinical studies. Also it was noted that motor recovery had a direct correlation with neuronal
survival, myelin preservation, and apoptosis reduction in treated groups [102, 107, 109, 110,
114, 117, 118]. As a consequence of these encouraging results, we have envisioned the possi‐
bility of combining this strategy with others that have also shown beneficial effects [103, 117,
unpublished data]. For that reason, A91‐immunization was administered along with gluta‐
thione monoethyl ester (GSHE), which is an anti‐oxidant capable of accelerating the immune
response and providing neuroprotection [104, 117]. The results of this study showed that after
a contusive or a compressive SCI, this combination induced better motor recovery, higher
number of myelinated axons, and better rubrospinal neuron survival than immunization
alone. These results open an interesting scenery for clinical studies.
Finally, in order to consider A91‐immunization for being used at clinical settings, it is of
relevance to contemplate vaccine safety. With this regard, immunizing with A91 shows no
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signs of autoimmune disease development, possibly due to its low affinity to major histocom‐
patibility complex (MHC) molecules [105]. Furthermore to evaluate vaccine safety, the clinical
appearance of treated animals was assessed, and no weight variation or other clinical data of
EAE in immunized animals was detected [106]. A91 has proven to be effective in several studies
conducted at different time points showing the stability of the vaccine in promoting recovery.
Preclinical results of studies evaluating vaccine efficacy indicate that this therapy could be
possibly applied to SCI patients and improve their recovery and quality of life.
4. Concluding statement
Injury to the spinal cord stimulates the appearance of innate and adaptive immune responses,
which could participate in either the pathogenesis or healing responses to trauma. The immune
system should not be suppressed; instead, it must be modulated to attain its beneficial effect.
That is why the use of immunosuppressant drugs like MP in the clinical field no longer seems
a rational treatment. As a physiological hemostatic self‐defense mechanism, PA is an essential
mechanism to be considered for the pathophysiology and treatment of SCI. Boosting PA with
the use of APL is needed in order to increase the functional recovery in the immune related
neurodegenerative diseases. In SCI, immunization with the APL A91 has proven to reduce
part of the immune‐related secondary injury mechanisms without the risk of developing an
autoimmune response. Preclinical results suggest that this therapy could be an effective
treatment for SCI recovery, as it is closely related to a higher motor improvement, which is the
most evident deficit in SCI patients. However, further studies related to the use of APL in SCI
are needed to translate this therapy to the clinical field. For instance, we have to ensure that
immunization with this peptide does not cause any side effect (i.e. hypersensitivity or
autoimmunity). Additionally, further experiments should be performed in order to find out
the best adjuvant to be used in humans, even the investigation should be directed to elucidate
if the use of adjuvants is really necessary. Finally, the dosing of the peptide as well as the
schedule of administration at clinical settings should also be investigated.
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